Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in patients with Myelodysplastic Syndrome (MDS)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telik

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of MDS

• Documented significant cytopenia for at least 2 months

• Adequate liver and kidney function

• Ineligible for stem cell bone marrow transplantation

• At least 18 years of age

• Discontinuation of growth factors (e.g., G-CSF) within 3 weeks of study entry

Exclusion Criteria:

• Prior bone marrow transplant

• Failure to recover from any prior surgery or any major surgery within 4 weeks of study entry

• Pregnant or lactating women

• Other investigational drugs within 14 days of study entry

• Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry